Percutaneous Device Closure of PVL: An Alternative to Surgery

Paravalvular Leak (PVL) occurs in 5 to 17% of patients undergoing surgical valve replacement. Percutaneous device closure of PVL represents an alternative to repeat surgery.   All centers in UK and Ireland performing percutaneous PVL closure delivered their data to the UK PVL registry. Data were analyzed for factors associated with mortality and major cardiovascular<a href="https://solaci.org/en/2016/10/06/percutaneous-device-closure-of-pvl-an-alternative-to-surgery/" title="Read more" >...</a>

Late Mortality in TAVR Is Mainly Due to Non-Cardiac Causes

Transcatheter aortic valve replacement (TAVR) has revolutionized the management of high-risk patients with severe aortic stenosis. However, survival after the procedure and severe complications have been assessed in relatively small populations with limited follow-up.   This article reports long-term clinical results in the FRANCE-2 (FRench Aortic National CoreValve and Edwards) registry.   The FRANCE-2 registry<a href="https://solaci.org/en/2016/10/05/late-mortality-in-tavr-is-mainly-due-to-non-cardiac-causes/" title="Read more" >...</a>

Martínez Ríos: “SOLACI Went from a Dream to a World-Renowned Society”

Dr. Marco Antonio Martínez Ríos comes from a family of physicians. “Studying Medicine was the most natural thing in the world for me,” admits Martínez Ríos, who in 1993 became president of the Latin American Group of Interventional Cardiology (Grupo Latinoamericano de Cardiología Intervencionista, GLACI), the seed that would grow to become SOLACI in 1994.  <a href="https://solaci.org/en/2016/09/27/martinez-rios-solaci-went-from-a-dream-to-a-world-renowned-society/" title="Read more" >...</a>

Paravalvular Insufficiency After TAVR: A Better Predictor of Endocarditis

Data from this large international registry associate endocarditis after a transcatheter aortic valve replacement (TAVR) with high rates of early and late mortality, and might help find predictors identifying patients with the highest risk of developing this rare but dangerous complication.   So far, information on endocarditis after TAVR was limited to small populations. In<a href="https://solaci.org/en/2016/09/16/paravalvular-insufficiency-after-tavr-a-better-predictor-of-endocarditis/" title="Read more" >...</a>

sapien xt vs. sapien 3 nuevas válvulas percutáneas

New TAVR Devices: Better Results in Bicuspids

Courtesy of del Dr. Carlos Fava.   The bicuspid aortic valve is highly anatomically challenging because of valve asymmetric calcification, increased annulus diameter, raphe calcification and ascending aorta dilation. The new valves have shown to improve results, but we still lack data on this group.   301 patients presenting bicuspid aortic valve undergoing transcatheter aortic<a href="https://solaci.org/en/2016/09/14/new-tavr-devices-better-results-in-bicuspids/" title="Read more" >...</a>

SAPIEN 3: Low One-Year-Mortality in High Risk or Inoperable Patients

In the first PARTNER trial (Placement of Aortic Transcatheter Valves), mortality at one year was 24% for high risk patients and 31% for inoperable patients. A recent report on SAPIEN 3 outcomes at 30 days ─ the last generation balloon expandable valve ─ showed a rather lower adverse events rate. However, additional information at longer<a href="https://solaci.org/en/2016/08/23/sapien-3-low-one-year-mortality-in-high-risk-or-inoperable-patients/" title="Read more" >...</a>

Bivalirudin or Heparin to Decrease Cerebral Embolization Post TAVI?

  Cerebral embolization is a relatively frequent complication during transcatheter aortic valve replacement (TAVR). The hypothesis behind this study is that the incidence of cerebral embolization might be decreased by anticoagulation with bivalirudin, instead of heparin.   The first study objective was to determine the proportion of patients with new cerebral embolus after TAVI and<a href="https://solaci.org/en/2016/08/19/bivalirudin-or-heparin-to-decrease-cerebral-embolization-post-tavi/" title="Read more" >...</a>

Pre-TAVI Mitral Regurgitation Is Associated with Higher Mortality

Courtesy of Dr. Carlos Fava.   This study sought to analyze the clinical impact and the level of improvement of mitral regurgitation (MR) in patients who receive a transcatheter aortic valve replacement (TAVR), and to find potential candidates for double valve repair with percutaneous techniques.   Of 1.110 patients included, 177 (15.9%) suffered from severe pre-TAVR mitral<a href="https://solaci.org/en/2016/08/16/pre-tavi-mitral-regurgitation-is-associated-with-higher-mortality/" title="Read more" >...</a>

Sex Specific Outcomes: Women after TAVI

Courtesy of Dr. Carlos Fava. The benefits of transcatheter aortic valve implantation (TAVI) have been widely shown, but there is no evidence on sex-specific outcomes. Some studies have shown lower mortality and better evolution of the ventricular function in women, yet with more bleeding and stroke; however, it remains unclear.   This study included 1,019 patients<a href="https://solaci.org/en/2016/08/10/sex-specific-outcomes-women-after-tavi/" title="Read more" >...</a>

Mismatch protésico en válvulas supra anulares y en válvulas intra anulares

Low BMI Is a Predictor of Death for TAVI

Courtesy of Dr. Carlos Fava.     Body mass index (BMI) has always played an important role in heart surgery. However, there is little evidence on BMI effects on TAVI. This study included 491 patients, which were divided according to BMI into:   low (<20 Kg/m2 ) normal (20-24.9 Kg/m2 ) overweight (25-30 Kg/m2 ) obese<a href="https://solaci.org/en/2016/08/03/low-bmi-is-a-predictor-of-death-for-tavi/" title="Read more" >...</a>